Supplemental immune globulins in sepsis

Area of Science:

• Critical Care Medicine
• Immunology
• Infectious Diseases

Background:

• Intravenous immune globulins (IVIG) are frequently used for sepsis, septic shock, and systemic inflammation in critically ill patients.
• The exact benefits and mechanisms of IVIG in sepsis are not fully established, despite its widespread application.

Purpose of the Study:

• To evaluate the efficacy of IVIG as a supplemental treatment for sepsis and related conditions.
• To explore the potential mechanisms of action for IVIG in critically ill patients.

Main Methods:

• Review of existing studies and clinical trials investigating IVIG in sepsis.
• Analysis of patient subgroups and specific outcomes such as mortality, morbidity, and infection incidence.
• Examination of proposed mechanisms including antibody-mediated effects and cytokine modulation.

Main Results:

• IVIG did not demonstrate a reduction in overall mortality for the general sepsis and septic shock population.
• The Score-based Immunoglobulin in Sepsis (SBITS) study showed moderate improvements in sepsis morbidity and multiple organ dysfunction syndrome.
• Individual small trials suggested mortality reduction in specific sepsis subgroups, requiring further confirmation.
• IVIG prophylaxis reduced the incidence of severe infections in at-risk patients and procedures.

Conclusions:

• IVIG is not a definitive cure for sepsis but may serve as a valuable component in the multifaceted treatment approach.
• IVIG appears to reduce morbidity and infection risk in certain patient populations and contexts.
• Further research is needed to confirm benefits in specific sepsis subgroups and optimize its therapeutic role.